Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

PURPOSE Molecular imaging and targeted radiotherapy are emerging fields in nuclear oncology. Five human somatostatin receptors (hsstr1-hsstr5) are known to be overexpressed to some degree on various tumors, sstr2 being the most important one. Clinically used somatostatin based radiopeptides target exclusively sstr2. The aim of this study was to develop novel analogues with a broader sstr profile for diagnostic (positron emission tomography and single-photon emission computed tomography) and radiotherapeutic applications. EXPERIMENTAL DESIGN The following promising structures emerged from a parallel synthetic approach: [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA(0)),1-Nal(3),Thr(8)]-octreotide (1, DOTA-NOC-ATE) and [DOTA(0),BzThi(3),Thr(8)]-octreotide (2, DOTA-BOC-ATE). The conjugates were labeled with cold and radioactive (111)In. Pharmacologic properties were compared with [(111)In-DOTA,Tyr(3)]-octreotide ([(111)In-DOTA]-TOC). RESULTS The receptor affinity profile showed high affinity of both peptides to hsstr2, hsstr3, and hsstr5 and some intermediate affinity to hsstr4, whereas [(111)In-DOTA]-TOC shows affinity only to sstr2. The internalization is fast in sstr2 expressing AR4-2J and in transfected sstr3 expressing human embryonic kidney 293 cells. Both radiopeptides internalize much more efficiently than [(111)In-DOTA]-TOC. Animal biodistribution studies showed very high and specific uptake of [(111)In]-1 and [(111)In]-2 in s.c. implanted AR4-2J tumors (Lewis rats) and in somatostatin receptor expressing normal tissues. The uptake was at least 2-fold higher in these tissues and in the tumor compared with [(111)In-DOTA]-TOC. In addition, the kidney uptake was significantly lower for both radiopeptides. CONCLUSIONS These data suggest that the novel radiopeptides are superior to [(111)In/(90)Y-DOTA]-TOC and show great promise for the clinical application in the imaging of somatostatin receptor-positive tumors and their targeted radiotherapy.

[1]  J. Stewart.  Solid Phase Peptide Synthesis , 1984 .

[2]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[3]  E. Krenning,et al.  Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  L. Travaini,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-Octreotide: Implications for internal radiotherapy with 90Y-DOTATOC , 2000 .

[5]  S. Lamberts,et al.  Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. , 2000, The Journal of clinical endocrinology and metabolism.

[6]  J. Edwardson,et al.  Fates of endocytosed somatostatin sst2 receptors and associated agonists. , 1998, The Biochemical journal.

[7]  J. Laissue,et al.  Immunohistochemical localization of somatostatin receptors sst2A in human tumors. , 1998, The American journal of pathology.

[8]  A. Schally,et al.  Human ovarian cancers express somatostatin receptors. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  G. Capellá,et al.  Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. , 1996, Cancer research.

[10]  D. Hoyer,et al.  Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. , 1994, Digestion.

[11]  J. Reubi,et al.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  G. Meno-Tetang,et al.  SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. , 2002, European journal of endocrinology.

[13]  J. Schmitt,et al.  Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. , 2003, Gynecologic oncology.

[14]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Waldherr,et al.  The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Lewis,et al.  Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. , 1999, Journal of medicinal chemistry.

[17]  T. Visser,et al.  Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy , 1997, European Journal of Nuclear Medicine.

[18]  R. Lefkowitz,et al.  Signalling: Seven-transmembrane receptors , 2002, Nature Reviews Molecular Cell Biology.

[19]  A. Schally,et al.  RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors , 2000 .

[20]  P. Smith-Jones,et al.  The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours , 1998, European Journal of Nuclear Medicine.

[21]  Eva Forssell-Aronsson,et al.  and Somatostatin Receptor Subtypes in Thyroid Tumors , 2000 .

[22]  J. Reubi,et al.  A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. , 2002, European journal of pharmacology.

[23]  S. Schulz,et al.  Differential β-Arrestin Trafficking and Endosomal Sorting of Somatostatin Receptor Subtypes* , 2004, Journal of Biological Chemistry.

[24]  S. Melmed,et al.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. , 1994, The Journal of clinical endocrinology and metabolism.

[25]  M. Hennig,et al.  Radiometal‐Labelled Macrocyclic Chelator‐Derivatised Somatostatin Analogue with Superb Tumour‐Targeting Properties and Potential for Receptor‐Mediated Internal Radiotherapy , 1999 .

[26]  B. Bernard,et al.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  T. O'Dorisio,et al.  Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. , 2002, Seminars in nuclear medicine.

[28]  E P Krenning,et al.  Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. , 1998, Cancer research.

[29]  G. Mengod,et al.  Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. , 1994, Cancer research.

[30]  Y. Menda,et al.  Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Sheppard,et al.  Solid phase peptide synthesis : a practical approach , 1989 .

[32]  Mu Wang,et al.  Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. , 2003, Cancer research.

[33]  J. Laissue,et al.  Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.

[34]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[35]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[36]  J. Mueller‐Brand,et al.  Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.

[37]  I. Sobhani,et al.  Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  M. Papotti,et al.  Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours , 2001, Virchows Archiv.